India has made an historic move towards tackling dengue with the approval of TAK-003 (Qdenga) by the Central Drugs Standard Control Organization (CDSCO) in mid-July 2026. It is a groundbreaking moment for India, which has approved its first ever dengue vaccine, thus providing hope against one of the toughest mosquito-borne diseases. Dengue cases have been increasing continuously since the past two decades, and approval of the vaccine is a major step forward in this regard for public health and preventive medicine.
Dengue remains a tough health challenge to overcome in tropical and subtropical areas especially during the monsoon season. This is due to the fact that the disease is caused by four similar strains of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4), which are spread through the bites of infected Aedes mosquitoes. While some of the infections cause flu-like symptoms in patients, severe dengue causes life-threatening illnesses like dengue hemorrhagic fever and dengue shock syndrome. Dengue management is made even more difficult due to the fact that infection by one type of serotype makes patients immune only against that type, making them vulnerable to other three types of serotypes.
Qdenga is a Japanese-made tetravalent vaccine made by Takeda Pharmaceuticals. It aims to offer immunity against all four dengue serotypes. It is delivered in two doses with a gap of three months between the two doses. The most important strength of Qdenga is that it can be taken regardless of prior dengue infection. Thus, there is no need for testing or screening before administering the vaccine.
CDSCO has approved Qdenga for people from 4 to 60 years old. The clinical trials have shown very promising results, with an average of 80% protection against the confirmed case of dengue infection and over 90% protection from hospitalization because of dengue. Such rates of effectiveness may significantly help in reducing the disease burden, number of hospitalizations, and expenses on healthcare services during seasonal outbreaks.
In India, there is an alarmingly high increase in dengue cases because of the rapid process of urbanization, climate changes, expansion of mosquito habitats, and increase in population density. According to the reports about health, there is an increase of more than eleven times in dengue cases during the last two decades.
Another important point about the approval is the cooperation between Takeda and Biological E, an Indian manufacturer of vaccines. Biological E is expected to contribute significantly to increasing production capacity in order to meet the needs for both domestic consumption and international demand. This collaboration contributes greatly to India's role in producing vaccines worldwide and ensures long-term availability of protection against dengue.
It is necessary to mention that although the vaccine has been developed successfully and is widely approved, healthcare specialists emphasize that vaccination is supposed to be only one of the methods to prevent dengue infection. The fact that mosquitoes keep infecting people regardless of their vaccination status means that there should be active participation from people in destroying stagnant water, keeping sanitary conditions, using insect repellent, having window screens, and dressing appropriately.
The approval of the vaccine demonstrates the efforts of India to integrate evidence-based practices in its health care system. Once real-life safety and effectiveness information becomes available after the widespread implementation of the vaccine, it will be much easier to understand how to incorporate the vaccine in national programs of immunizations.
It can be stated that the approval of Qdenga by the CDSCO has been a historic landmark for India in its fight against dengue. By merging scientific progress with mosquito control and health education, India has a new weapon to combat the effects of a disease that has affected millions of people. Although no single approach is going to stop dengue completely, the development of the very first dengue vaccine in the country signifies the start of a new era.
Team Yuva Aaveg-
Adarsh Tiwari
🌟 Join Yuva Aaveg! 🌟
A vibrant community dedicated to empowering youth with the latest insights, discussions, and updates on topics that matter. Connect with like-minded individuals, share ideas, and stay inspired to make a difference.
📲 Join us on WhatsApp and Telegram for exclusive updates and engaging conversations!
No comments:
Post a Comment
Please give your feedback and help us to give you best possible content!!